NRG Therapeutics
Stevenage, United Kingdom · Biotechnology, Health Care, Therapeutics
NRG Therapeutics is a neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND).
Funding history
- Funding Round · $67.0M · Sep 2025
- Series A · $16.0M · Nov 2022
Recent signals
- Aug 03, 2026: NRG Therapeutics Appoints Claus Sundgreen as Chief Medical Officer
- Dec 05, 2025: NRG Therapeutics Appoints Paul Thompson as Chief Development Officer
- Sep 08, 2025: Raised $67.0M in Funding Round
- Nov 09, 2022: Raised $16.0M in Series A
See plans & pricing → Track NRG Therapeutics’s funding, hiring and signals, with verified contacts, on Fundz.
Fundz watches NRG Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.